Who are Saw palmetto berry extract's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pre-randomization Dutasteride, Dutasteride Capsules, Dutasteride/Tamsulosin, Combodart®, Maintenance of alpha-blocker and 5-ARI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saw-palmetto-berry-extract.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Saw palmetto berry extract — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saw palmetto berry extract (Saw palmetto berry extract) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract; 5-alpha reductase inhibitor. Area: Urology.

marketed Herbal extract; 5-alpha reductase inhibitor 5-alpha reductase; androgen receptor (indirect) Urology Small molecule Live · refreshed every 30 min

Target snapshot

Saw palmetto berry extract (Saw palmetto berry extract) — A. Vogel AG. Saw palmetto berry extract inhibits 5-alpha reductase and blocks androgen receptor signaling to reduce prostate inflammation and improve urinary symptoms associated with benign prostatic hyperplasia.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saw palmetto berry extract TARGET	Saw palmetto berry extract	A. Vogel AG	marketed	Herbal extract; 5-alpha reductase inhibitor	5-alpha reductase; androgen receptor (indirect)
Pre-randomization Dutasteride	Pre-randomization Dutasteride	Siami, Paul F., M.D.	marketed	5-alpha reductase inhibitor	5-alpha reductase (type 1 and type 2)
Dutasteride Capsules	Dutasteride Capsules	UConn Health	marketed	5-alpha reductase inhibitor	5-alpha reductase (type 1 and type 2)
Dutasteride/Tamsulosin	Dutasteride/Tamsulosin	GlaxoSmithKline	marketed	5-alpha reductase inhibitor / alpha-1 adrenergic antagonist combination	5-alpha reductase (type I and II) / alpha-1A adrenergic receptor
Combodart®	Combodart®	Ache Laboratorios Farmaceuticos S.A.	phase 3	Combination therapy: 5-alpha reductase inhibitor + alpha-1A adrenergic antagonist	5-alpha reductase (types I and II); alpha-1A adrenergic receptor
Maintenance of alpha-blocker and 5-ARI	Maintenance of alpha-blocker and 5-ARI	Gangnam Severance Hospital	phase 3	Alpha-blocker and 5-alpha reductase inhibitor combination	Alpha-1 adrenergic receptor and 5-alpha reductase enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract; 5-alpha reductase inhibitor class)

A. Vogel AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saw palmetto berry extract — Competitive Intelligence Brief. https://druglandscape.com/ci/saw-palmetto-berry-extract. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab